463967-83-1

Basic information

• Product Name: Carbamic acid, [(2S)-2-hydroxypropyl]-, phenylmethyl ester
• CAS NO: 463967-83-1
• Molecular Formula: C11H15NO3
• Molecular Weight: 209.245
• Mol File: 463967-83-1.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: Carbamic acid, [(2S)-2-hydroxypropyl]-, phenylmethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [(2S)-2-hydroxypropyl]-, phenylmethyl ester(463967-83-1)
• EPA Substance Registry System: Carbamic acid, [(2S)-2-hydroxypropyl]-, phenylmethyl ester(463967-83-1)

Safety Data

• Hazardous Substances Data: 463967-83-1(Hazardous Substances Data)

Upstream product

• 2799-17-9 (S)-1-amino-2-propanol 
• 501-53-1 benzyl chloroformate 
• 65935-10-6 1-Benzyloxycarbonylamino-2,4-propanediol 
• 111491-97-5 (2-oxopropyl)carbamic acid benzyl ester 

Downstream Products

• 251325-35-6 (S)-1-[(benzyloxycarbonyl)amino]-2-propanol tosylate 
• 251325-34-5 toluene-4-sulfonic acid (S)-2-benzyloxycarbonylamino-1-methyl-ethyl ester 
• 883907-25-3 (R)-2-(benzyloxycarbonyl)amino-1-methylethyl thioacetate 

Relevant articles and documents

A Straightforward Deracemization of sec-Alcohols Combining Organocatalytic Oxidation and Biocatalytic Reduction

An efficient organocatalytic oxidation of racemic secondary alcohols, mediated by sodium hypochlorite (NaOCl) and 2-azaadamantane N-oxyl (AZADO), has been conveniently coupled with a highly stereoselective bioreduction of the intermediate ketone, catalyzed by ketoreductases, in aqueous medium. The potential of this one-pot two-step deracemization process has been proven by a large set of structurally different secondary alcohols. Reactions were carried out up to 100 mm final concentration enabling the preparation of enantiopure alcohols with very high isolated yields (up to 98 %). When the protocol was applied to the stereoisomeric rac/meso mixture of diols, these were obtained with very high enantiomeric excesses and diastereomeric ratios (95 % yield, >99 % ee, >99: 1 dr).

Development of a supply route for the synthesis of an iNOS inhibitor: Complications of the key SN2 reaction

The original medicinal chemistry synthesis of an iNOS inhibitor presented several challenges that had to be overcome in order to constitute a supply route suitable for operation on a multikilo scale. The key step in the synthesis is an SN2 reac

COMBINATION THERAPY WITH INHIBITORS OF INDUCIBLE NITRIC OXIDE SYNTHASE AND ALKYLATING AGENTS

A combination therapy comprising administration of a carbamoylating chemotherapeutic agent in conjunction with administration of a selective iNOS inhibitor compound is disclosed. Optionally, resection and radiation therapy are provided with the therapeutic combination. A medicament comprising a carbamoylating chemotherapeutic agent and a selective iNOS inhibitor compound together with a pharmaceutically acceptable carrier is further disclosed. A kit comprising a carbamoylating chemotherapeutic agent and a selective iNOS inhibitor compound is further disclosed.